Drug intelligence / Profile preview

ADC2431

Development stage: Preclinical
Lead developer: Hangzhou Adcoris Biopharmaceuticals
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ADC2431 (also known as ACR431) is a first-in-class, immunomodulatory antibody-drug conjugate (ADC) being developed by Hangzhou Adcoris Biopharmaceuticals for the treatment of solid tumors and pan-cancer. The therapeutic targets an undisclosed novel antigen and is designed with an immunomodulatory mechanism of action. ADC2431 is currently in IND-enabling preclinical development, with an Investigational New Drug (IND) application submission planned for the second quarter of 2027.

Beyond the preview

Go deeper on ADC2431.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADC2431.

Explore the full profile